Kamin W, Maydannik V, Malek F A, Kieser M
University Hospital Pediatrics, Mainz, Germany.
Int J Clin Pharmacol Ther. 2010 Mar;48(3):184-91. doi: 10.5414/cpp48184.
The study aim was to demonstrate the efficacy and to investigate the tolerability of EPs 7630, a herbal drug preparation from Pelargonium sidoides roots, in the treatment of patients (1 - 18 years) with acute bronchitis outside the strict indication for antibiotics.
A total of 200 patients were randomized to receive either active drug containing EPs 7630 (1 - 6 years: 3 x 10 drops/d; > 6 - 12 years: 3 x 20 drops/d; > 12 - 18 years: 3 x 30 drops/d) or placebo for 7 consecutive days.
change in the total score of bronchitis-specific symptoms (BSS) from Day 0 to Day 7. Main secondary outcome measures: treatment outcome, patients' satisfaction with treatment, onset of effect, bed rest.
From baseline to Day 7, the mean BSS score improved significantly more for EPs 7630 compared with placebo (3.4 +/- 1.8 vs. 1.2 +/- 1.8 points, p < 0.0001). On Day 7, treatment outcome was significantly better (p < 0.0001), satisfaction with treatment more pronounced (77.6% vs. 25.8%, p < 0.0001), onset of effect faster, and time of bed rest shorter as compared with placebo. Tolerability was similarly good in both groups. All adverse events were assessed as non-serious.
EPs 7630 was shown to be efficacious and safe in the treatment of acute bronchitis in children and adolescents outside the strict indication for antibiotics with patients treated with EPs 7630 perceiving a more favorable course of the disease and a good tolerability as compared with placebo.
本研究旨在证明从香叶天竺葵根中提取的草药制剂EPs 7630在治疗无严格抗生素使用指征的1 - 18岁急性支气管炎患者中的疗效,并调查其耐受性。
总共200名患者被随机分为两组,一组连续7天接受含EPs 7630的活性药物治疗(1 - 6岁:每日3次,每次10滴;6 - 12岁:每日3次,每次20滴;12 - 18岁:每日3次,每次30滴),另一组接受安慰剂治疗。
从第0天到第7天支气管炎特异性症状(BSS)总分的变化。主要次要观察指标:治疗结果、患者对治疗的满意度、起效时间、卧床休息时间。
从基线到第7天,与安慰剂相比,EPs 7630组的平均BSS评分改善更为显著(3.4±1.8分对1.2±1.8分,p<0.0001)。在第7天,与安慰剂相比,治疗结果显著更好(p<0.0001),对治疗的满意度更高(77.6%对25.8%,p<0.0001),起效更快,卧床休息时间更短。两组的耐受性同样良好。所有不良事件均被评估为不严重。
在治疗无严格抗生素使用指征的儿童和青少年急性支气管炎方面,EPs 7630被证明是有效且安全的,与安慰剂相比,接受EPs 7630治疗的患者感觉疾病进程更有利,耐受性良好。